@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_head { this: np:hasAssertion dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_assertion; np:hasProvenance dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_provenance; np:hasPublicationInfo dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_publicationInfo; a np:Nanopublication . dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_assertion a np:Assertion . dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_provenance a np:Provenance . dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_publicationInfo a np:PublicationInfo . } dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_assertion { miriam-gene:1956 a ncit:C16612 . lld:C0877373 a ncit:C7057 . dgn-gda:DGNf12290e636206b05b6e3aac0fff92eb5 sio:SIO_000628 miriam-gene:1956, lld:C0877373; a sio:SIO_001121 . } dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_provenance { dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_assertion dcterms:description "[The initial set of trials will focus on different questions: (1) Exceptional Responders Initiative-why do a minority of patients with solid tumors or lymphoma respond very well to some drugs even if the majority do not?; (2) NCI MATCH trial-can molecular markers predict response to targeted therapies in patients with advanced cancer resistant to standard treatment?; (3) ALCHEMIST trial-will targeted epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors improve survival for adenocarcinoma of the lung in the adjuvant setting?; and (4) Lung Cancer Master Protocol trial for advanced squamous cell lung cancer-is there an advantage to developing drugs for small subsets of molecularly characterized tumors in a single, multiarm trial design?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:24857062; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP1185024.RAmvCVKLC6H0Mi-IlD-m8oX84k1O4-vmwahVf3dcYyMNQ130_publicationInfo { this: dcterms:created "2016-05-13T12:50:43+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }